The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Podgornyaya M.S.

Samara State Medical University

Tselkovich L.S.

Samara State Medical University

Balter R.B.

Samara State Medical University

Ivanova T.V.

Samara State Medical University

Il'chenko O.A.

Samara State Medical University

The possibilities of realizing reproductive function in women with endometrial hyperplasia

Authors:

Podgornyaya M.S., Tselkovich L.S., Balter R.B., Ivanova T.V., Il'chenko O.A.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5): 98‑105

DOI: 10.17116/rosakush20252505198

Read: 187 times

Buy for 300₽
Contact the author
Table of contents

THE POSSIBILITIES OF REALIZING REPRODUCTIVE FUNCTION IN WOMEN WITH ENDOMETRIAL HYPERPLASIA
THE POSSIBILITIES OF REALIZING REPRODUCTIVE FUNCTION IN WOMEN WITH ENDOMETRIAL HYPERPLASIA

To cite this article:

Podgornyaya MS, Tselkovich LS, Balter RB, Ivanova TV, Il'chenko OA. The possibilities of realizing reproductive function in women with endometrial hyperplasia. Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5):98‑105. (In Russ.)
https://doi.org/10.17116/rosakush20252505198

 
Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Prognosis and prevention of recu­rrent and atypical endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):59-65
Features of changes in hormone rece­ptor expression during therapy in women of reproductive age with hype­rplastic processes in the endo­metrium. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):21-28
Comparative analysis of the effe­ctiveness of therapy for endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):75-83
Use of gona­dotropic releasing hormone agonists in hype­rplastic syndrome in gyne­cology. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):51-58
A rare case of endo­metrial stro­mal sarcoma of the cervix and vagina in a 17-year-old patient with abno­rmal uterine bleeding. Russian Journal of Human Reproduction. 2025;(2):86-91
Mali­gnancy of fibrous dysplasia of the calvarial bone in patient with McCune-Albright syndrome: clinical obse­rvation and lite­rature review. Burdenko's Journal of Neurosurgery. 2025;(4):87-97
Abstract:

Based on the analysis of published works, risk factors and causes of hyperplastic processes in the endometrium are presented. The stages of formation and forms of endometrial hyperplasia are highlighted. The pathogenetic mechanisms of reproductive dysfunction in endometrial hyperplasia are described. The need for sufficiently long-term (more than 6 months) hormone therapy, the use of all methods to normalize fat metabolism, and the mandatory use of a personalized approach to treatment is emphasized. Endometrial hyperplasia in women of late reproductive age is not an absolute contraindication to the onset and prolongation of pregnancy, proper management of patients allows you to preserve the possibility of conception and gestation. The results of research aimed at understanding the mechanisms of reproductive dysfunction in endometrial hyperplasia are very significant and require further study.

Keywords:

endometrial hyperplasia
realization of reproductive function
the value of estrogen and progesterone
premenopausal age
malignancy
abnormal uterine bleeding

Authors:

Podgornyaya M.S.

Samara State Medical University

Tselkovich L.S.

Samara State Medical University

Balter R.B.

Samara State Medical University

Ivanova T.V.

Samara State Medical University

Il'chenko O.A.

Samara State Medical University

Received:

18.07.2025

Accepted:

31.07.2025

Close metadata

References:

  1. Gabidullina RI, Smirnova GA, Nukhbala FR. Endometrial hyperplastic processes: Modern management of patients. Gynekologiya. 2019;21:6:53-58. (In Russ.).
  2. Dolgushina NV, Adamyan LV, Sheshko EL. Late reproductive age in women: Risks of reproductive function disorders (Literature Review). Russian Journal of Human Reproduction. 2023;29:4:99-106. (In Russ.). https://doi.org/10.17116/repro20232904199
  3. Anderson RA, Amant F, Braat D, D’Angelo, De Souza Lopez SMK, Demeister A, Dweck S, Frith L, Lambertini M, Maslin K. ESHRE’s Guide: Preserving Female Fertility. Hum Reprod Open. 2020;4:hoaa052. https://doi.org/10.1093/hropen/hoaa052
  4. Di Nizio V, Daponte N, Messini K, Anifandis G, Antonouli S. Oncofertility and fertility preservation in women with gynecological malignancies: at what stage are we today? Biomolecules. 2024;14:8:943.  https://doi.org/10.3390/biom14080943
  5. Pathare ADS, Loid M, Saare M, Gidlöf SB, Zamani Esteki M, Acharya G, Peters M, Salumets A. Endometrial receptivity in women of advanced age: an underrated factor in infertility. Hum Reprod Update. 2023;29:6:773-793.  https://doi.org/10.1093/humupd/dmad019
  6. Mikwar M, MacFarlane AJ, Marchetti F. Mechanisms of oocyte aneuploidy associated with advanced maternal age. Mutat Res Rev Mutat Res. 2020;785:108320. https://doi.org/10.1016/j.mrrev.2020.108320
  7. Eijkemans MJC, van Poppel F, Habbema DF, Smith KR, Leridon H, te Velde ER. Too old to have children? Lessons from natural fertility populations. Hum Reprod. 2014;29:6:1304-1312. https://doi.org/10.1093/humrep/deu056
  8. Alper ECD, Coşkun ADE, Vural F. Comparison of nonspecific inflammatory markers in endometrial cancer and hyperplasia. Rev Assoc Med Bras. 2021;67:7:966-970.  https://doi.org/10.1590/1806-9282.20210318
  9. Damirov MM, Nefedova GA, Ierusalimskii AP. Modern morphological classification of endometrial hyperplasia from the perspective of a clinician. Vestnik Ivanovskoi meditsinskoi akademii. 2024;29:3:53-61. (In Russ.). https://vestnik-ivgma.ru/attachments/921?locale=en
  10. Dumanovskaya MR, Chernukha GE, Tabeeva GI, Asaturova AV. Endometrial hyperplasia: Search for optimal solutions and strategies. Akusherstvo i ginekologiya. 2021;4:23-31. (In Russ.). https://doi.org/10.18565/aig.2021.4.23-31
  11. Zhao J, Hu Y, Zhao Y, Chen D, Fang T, Ding M. Risk factors for endometrial cancer in patients with endometrial hyperplasia: implications for clinical management. BMC Women’s Health. 2021;21:312.  https://doi.org/10.1186/s12905-021-01452-9
  12. Centini G, Colombi I, Ilaria I, Federica P, Alessandro G, Alberto C, Nasser H, Ramon RN, Francesco GM, Diego R, Lucia L, Errico Z. Fertility preservation in endometrial cancer: where are we now? Cancers. 2025;17:1:112.  https://colab.ws/articles/10.3390/cancers17010112
  13. Doherty MT, Sunny OB, Coleman HG, Cardwell ChR, Mcclaggage VG, Quinn D, Wiley J, McMenamin UK. Concomitant and future risk of endometrial cancer in women with endometrial hyperplasia: a systematic review and meta-analysis. PLOS ONE. 2020;15:4:0232231.
  14. Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, Yano T. The effect of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer. 2013;23:2:288-293.  https://doi.org/10.1097/IGC.0b013e31827c18a1
  15. Inoue O, Hamatani T, Susumu N, Yamagami V, Ogawa S, Takemoto T. Factors influencing pregnancy outcome in young women who received fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2016;14:2.  https://doi.org/10.1186/s12958-015-0136-7
  16. Mutlu L, Manavella DD, Gullo G, McNamara B, Santin AD, Patrizio P. Endometrial cancer in the reproductive age: a fertility-preserving approach and reproductive outcomes. Cancers. 2022; 14:5187. https://doi.org/10.3390/cancers14215187
  17. Ogunbiyi MO, Oxley S, Graham R, Olaitan A. Oncological and reproductive outcomes of fertility-preserving treatments for stage 1, grade 1 endometrial carcinoma: a systematic review and meta-analysis. J Obstet Gynaecol. 2024;44:221. 
  18. Chernukha GE, Asaturova AV, Ivanov IA, Dumanovskaya MR. Structure of Endometrial Pathology in Different Age Groups. Akusherstvo i ginekologiya. 2018;8:129-134. (In Russ.). https://doi.org/10.18565/aig.2018.8.129-134
  19. Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23:2:232-254.  https://doi.org/10.1093/humupd/dmw042
  20. Luccini SM, Esteban A, Nigra MA, Palacios AT, Alzate-Granados JP, Borla HF. Updated information on conservative treatment of endometrial cancer in patients younger than 45 years. Gynecol Oncol. 2021;161:3:802-809.  https://doi.org/10.1016/j.ygyno.2021.04.017
  21. Harrison RF, He W, Fu S, Zhao H , Sun CC , Suidan RS , Woodard TL, Rauh-Hain JA , Westin SN, Giordano SH, Meyer LA. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019;221:5:474.e1-474.e11.  https://doi.org/10.1016/j.ajog.2019.05.029
  22. Park JE, Yu EJ, Lee N, Park JE, Seong SJ, Lee WS, Lee HJ. Analysis of in vitro fertilization results after fertility-supporting therapy for endometrial hyperplasia or carcinoma. Gynecol Obstet Invest. 2024;89:6:461-468.  https://doi.org/10.1159/000539315
  23. Wang X, Aziz AUR, Wang D, Wang Y, Liu M, Yu X, Wang D. Predictive factors and survival rates in immunohistochemical detection of molecular subtypes of endometrial cancer: an analysis of 576 clinical cases. Diagn Pathol. 2024;19:162.  https://doi.org/10.1186/s13000-024-01584-0
  24. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. 2015;125:5:1272-1278. https://doi.org/10.1097/01.AOG.0000465189.50026.20
  25. Salamova KK, Saprykina LV, Ramazanova AM, Mil’dzikhova ZT, Stolyarova EV. Clinical features of patients with endometrial hyperplastic processes. RMZh. Mat’ i ditya. 2021;2:124-129. (In Russ.). https://doi.org/10.32364/2618-8430-2021-4-2-124-129
  26. Espaeva RN, Kenzhegalieva AB, Kudaibergenova LT, Sanatbaeva AA, Safonov NA, Yuan’ DL, Zhappar ZA. Endometrial hyperplasia as the main link in the pathogenesis of DMK. Vestnik KazNMU. 2019;3:1-3. (In Russ.). file:///C:/Users/User/Downloads/giperplaziya-endometriya-kak-osnovnoe-zveno-v-patogeneze-dmk.pdf
  27. Sviridova NI, Tkachenko LV, Yakhontova MA, Gritsenko IA, Maksimov SN, Puryaseva KA. Hyperplastic processes of the endometrium: modern approaches to diagnosis and treatment. Akusherstvo, ginekologiya, i reproduktsiya. 2024;18:1:83-95. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.464
  28. Erofeeva LG, Sidorkina AG, Novopashina GN, Erofeev BB. Modern understanding of the problem of endometrial hyperplasia. Nauchnoe obozrenie. Meditsinskie nauki. 2022;6:82-88. (In Russ.). https://science-medicine.ru/ru/article/view?id=1308
  29. Prip CM, Stentebjerg M, Bennetsen MH, Petersen LK, Bor P. Risk of atypical hyperplasia and endometrial carcinoma after initial diagnosis of non-atypical endometrial hyperplasia: A long-term follow-up study. PLoS ONE. 2022;17:4:Art. ID: e0266339. https://doi.org/10.1371/journal.pone.0266339
  30. Eun Bi Chan, Jin Lee, Kyung Ah So, Song Joo Lee, Ji Yong Lee, Tae Jin Kim, Park Eunhyang, Soon Beom Kang, Seung Hyuk Shim. Risk factors for recurrence in patients with early endometrioid endometrial cancer who achieved complete remission after hormonal treatment that reduces fertility. Gynecol Oncol. 2024;191:19-24.  https://www.gynecologiconcology-online.net/article/S0090-8258(24)01139-9/abstract
  31. Ordiyants IM, Kuular AA, Yamurzina AA, Guseinova RG, Novginov DS. Genetic and epigenetic mechanisms of endometrial hyperplasia development in women of reproductive age. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2020;8:3:67-70. (In Russ.).
  32. Kogan EA, Stanoevich IV, Kudrina EA, Ishchenko AI. Morphological and immunohistochemical parallels in endometrial hyperplasias. Arkhiv patologii. 2007;6:21-24. (In Russ.). https://elib.fesmu.ru/Article.aspx?id=175426
  33. Fox K, Maureen S, Chong JV, Scott RT Jr, Leslie BA. Local and systemic factors and implantation: what is the evidence? Fertil Steril. 2016;105:4:873-884.  https://doi.org/10.1016/J.fertnstert.2016.02.018
  34. Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson AL. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol. 2019;34:5:499-507.  https://doi.org/10.1007/s10654-018-0474-9
  35. Bakour SH, Gupta JK, Khan KS. Risk factors associated with endometrial polyps in abnormal uterine bleeding. Int J Gynaecol Obstet. 2002;76:2:165-168.  https://doi.org/10.1016/s0020-7292(01)00548-3
  36. Ding Y, Fan Y, Li S, Wang Y, Wang J, and Tian L. Metabolic syndrome is an independent risk factor that affects the time to complete remission in patients with atypical endometrial hyperplasia and early-stage endometrial cancer. Reprod Biol Endocrinol. 2022;20:1:134.  https://doi.org/10.1186/s12958-022-01006-0
  37. Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74:3:478-497.  https://doi.org/10.1007/s12020-021-02884-x
  38. Renehan AG, Tyson M, Egger M, Heller RF, Tsvalen M. Body mass index and cancer incidence: a systematic review and meta-analysis of prospective observational studies. Lancet (London, England). 2008;371:9612:569-578.  https://doi.org/10.1016/S0140-6736(08)60269-X
  39. Imasheva B, Kamaliev M, Lokshin V, Baimuratova M, Turekhanova A. A modern view on the study of risk factors leading to the malignization of hyperplastic endometrial processes: A review of the literature. Reproduktivnaya meditsina (Central Asia). 2022;4:53:22-31. (In Russ.). https://doi.org/10.37800/RM.3.2022.22-31
  40. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL; Society of Gynecologic Oncology Clinical Practice Committee. Management of Endometrial Precancers. Obstetrics and Gynecology. 2012;120:5:1160-1175. https://doi.org/10.1097/aog.0b013e31826bb121
  41. Li X, Fan Y, Wang J, Zhou R, Tian L, Wang Y, Wang J. Insulin resistance and metabolic syndrome increase the risk of recurrence during fertility-preserving treatment in patients with atypical endometrial hyperplasia and early endometrial cancer. Front Oncol. 2021;11:744689.
  42. Gokula Priya M, Bargavi E, Julega KS. An overview of endometrial hyperplasia. JMPAS. 2021;4:16-21.  https://jmpas.com/doi.org/1621105560
  43. Li X, Feng Y, Lin J-F, Billig H, Shao R. Endometrial resistance to progesterone and polycystic ovary syndrome. J Biomed Sci. 2014;21:2.  https://doi.org/10.1186/1423-0127-21-2
  44. Podzolkova NM, Korennaya VV. Modern ideas about the etiology, pathogenesis, and principles of treatment of endometrial hyperplasia. Akusherstvo i ginekologiya. 2021;8:192-199. (In Russ.). https://doi.org/10.18565/aig.2021.8.192-199
  45. Volotskaya NI, Golubinskaya EP, Zyablitskaya EYu, Maksimova PE. Chronic inflammation in simple endometrial hyperplasia. Krymskii zhurnal eksperimentalnoi i klinicheskoi meditsiny. 2023;13:4:14-21. (In Russ.).
  46. Likhacheva VV, Zorina VN, Tret’yakova YaN, Bazhenova LG, Tret’yakova TV, Renge LV. Modern ideas about the pathogenesis of chronic endometritis. Russian Bulletin of Obstetrician-Gynecologist. 2017;17:4:25-32. (In Russ.). https://doi.org/10.17116/rosakush201717425-32
  47. Chistyakova GN, Grishkina AA, Remizova II. Endometrial hyperplasia: Classification, pathogenesis features, and diagnostics (literature review). Russian Journal of Human Reproduction. 2018; 24:5:53-57. (In Russ.). https://doi.org/10.17116/repro20182405153
  48. Contreras NA, Sabadell H, Verdager P, Julia K, Fernandez-Montoli ME. Approaches to fertility preservation in patients with atypical endometrial hyperplasia and endometrial cancer: current data and future directions. Int J Mol Sci. 2022;23:2531. https://doi.org/10.3390/ijms23052531
  49. Kotel’nikova NA, Balter RB, Tselkovich LS, Ivanova TV, Il’chenko OA, Podgornyaya MS, Rudenko YuA. Risk factors for the development of hyperplastic processes in reproductive age. Features of the clinical picture of the disease. Sovremennaya nauka: aktual’nye problemy teorii i praktiki. Seriya: estestvennye i tekhnicheskie nauki. 2025;1:207-214. (In Russ.).
  50. Seregina DS, Nikolaenkov IP, Kuz’minykh TU. Obesity is a leading pathogenetic link in the pathological course of pregnancy and childbirth. Zhurnal akusherstva i zhenskikh boleznei. 2020;69:2:73-82. (In Russ.). https://doi.org/10.17816/JOWD69273-82
  51. Serova OF, Dobrokhotova YuE, Borovkova EI, Charkhifalakyan AV. Possibilities of preserving reproductive function in patients with atypical hyperplasia and initial endometrial cancer. RMZh. Mat’ i ditya. 2023;6:4:352-361. (In Russ.). https://doi.org/10.32364/2618-8430-2023-6-4-5
  52. Sabantsev MA, Shramko SV, Levchenko VG, Volkov OA, Tret’yakova TV. Endometrial hyperplasias: without atypia and with atypia. Ginekologiya. 2021;23:1:18-24. (In Russ.). https://doi.org/10.26442/20795696.2021.1.200666
  53. Deligdisch L. Hormonal pathology of the endometrium. Modern Pathology. 2000;13:3:285-294.  https://doi.org/10.1038/modpathol.3880050
  54. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Modern Pathology. 2000;13:3:309-327.  https://doi.org/10.1038/modpathol.3880053
  55. Gunin AG, Mashin IN, Zakharov DA. Proliferation, mitosis orientation and morphogenetic changes in the uterus of mice following chronic treatment with both estrogen and glucocorticoid hormones. J Endocrinol. 2001;169:1:23-31.  https://doi.org/10.1677/joe.0.1690023
  56. Mamikonyan IO, Sarkisov SE, Sattarov ShN, Boiko MA, Gyurdzhyan SA. Tamoxifen-associated endometrial pathology and its correction possibilities. Akusherstvo i ginekologiya. 2013;3:33-37. (In Russ.). https://aig-journal.ru/articles/Tamoksifen-associrovannaya-patologiya-endometriya-i-vozmojnosti-ee-korrekcii.html
  57. Stenina MB, Protasova AE, Samushiya MA, Yureneva SV. Practical recommendations for the correction of hormone-mediated side effects of antitumor therapy. RUSSCO Practical Recommendations, Part 2. Zlokachestvennye opukholi. 2023;13:#3s2:310-318. (In Russ.).
  58. Mal’tseva LI, Smolina GR, Sharipova RI, Bagaeva MI, Petryanina EV, Stovbun SV. Chronic Endometritis in the Practice of an Obstetrician-Gynecologist. Russian Bulletin of Obstetrician-Gynecologist. 2015;15:5:102-105. (In Russ.). https://doi.org/10.17116/rosakush2015154102-105
  59. Kutsenko II, Khorol’skaya EA, Safronova YuS. Optimization of preparation for pregnancy in patients with endometrial hyperplastic processes. Vestnik RUDN, series «Medicine». Akusherstvo i ginekologiya. 2011;1:254-260. (In Russ.).
  60. Tolibova GKh, Tral’ TG, Kakhiani MI. Possibilities of correcting the endometrial receptor profile in chronic endometritis. Akusherstvo i ginekologiya. 2024;10:121-128. (In Russ.). https://doi.org/10.18565/aig.2024.244
  61. Parisi F, Fenizia K, Introini A, Zavatta A, Scaccabarozzi K, Biasin M, Savazi V. The pathophysiological role of estrogens in the early stages of pregnancy: molecular mechanisms and clinical implications for pregnancy outcome from conception to the end of the first trimester. Hum Reprod Update. 2023;29:6:699-720.  https://doi.org/10.1093/humupd/dmad016
  62. Krasnopol’skaya KV, Novikova OV, Isakova KM, Shostenko LV, Rau DI, Shishkina AV. Endometrial hypoplasia in In Vitro Fertilization Programs in patients after treatment of atypical hyperplasia and early endometrial cancer. Russian Journal of Human Reproduction. 2023;29:1:57-62. (In Russ.). https://doi.org/10.17116/repro20232901157
  63. Islamidi DK, Belykh NS, Kovalev VV, Milyaeva NM. Contribution of the uterine cavity microbiota to the development of pathological endometrial processes. Ural’skii meditsinskii zhurnal. 2023; 22:1:96-103. (In Russ.). https://doi.org/10.52420/2071-5943-2023-22-1-96-103
  64. Walter-António MRS, Chen J, Multinu F, Hokenstad A, Distad TJ, Cheek EH, Keeney GL, Creedon DJ, Nelson H, Mariani A, Chia N. Potential contribution of the uterine microbiome to endometrial cancer development. Genome Med. 2016;8:122.  https://doi.org/10.1186/s13073-016-0368-y
  65. Korsak VS, Smirnova AA, Shurygina OV. Register of ART of the All-Russian Public Organization «Russian association of human reproduction». Report for 2020. Problemy reproduktsii. 2022; 28:6:12-27. (In Russ.). https://doi.org/10.17116/repro20222806112
  66. Novikova OV, Avasova ChA, Novikova EG. A new option for hormonal treatment of atypical hyperplasia and early endometrial cancer while preserving fertility. Onkoginekologiya. 2019;1:36-45. (In Russ.). https://doi.org/10.52313/22278710_2019_1_36
  67. Pashov AI, Tskhai IB, Sivova EN. The first experience of organ-preserving treatment of women of reproductive age with initial forms of endometrial cancer. Mat’ i ditya v Kuzbasse. 2010;1:132-134. (In Russ.).
  68. Kotel’nikova NA, Balter RB, Ivanova TV, Tselkovich LS, Il’chenko OA, Podgornaya MS. Features of changes in the expression of hormonal receptors in the background of the carried out therapy in women of reproductive age with hyperplastic processes in the endometrium. Russian Bulletin of Obstetrician-Gynecologist. 2025;25:2:21-28. (In Russ.). https://doi.org/10.17116/rosakush20252502121
  69. Orazov MR, Khamoshina MB, Mullina IA, Artemenko YuS. Endometrial hyperplasia: From pathogenesis to effective therapy. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2021;9:3:21-28. (In Russ.). https://doi.org/10.33029/2303-9698-2021-9-3-21-28
  70. Yang B, Xu Y, Zhu C, Xie L, Shang V, Ning S. The effectiveness of comprehensive hysteroscopic examination and resection of formations in combination with progestogen therapy in young women with atypical endometrial hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55-62.  https://doi.org/10.1016/J.ygyno.2019.01.014
  71. Bitsadze VO, Akin’shina SV, Khizroeva DKh, Makatsaria NA, Stuleva NS, Mashkova TM. Pathogenetic rationale for the use of natural progesterone in obstetric practice. Akusherstvo. Ginekologiya. Reproduktsiya. 2014;8:2:79-88. (In Russ.).
  72. Haas J, Smith R, Silberberg E, Naylor D, Meriano J, Barzilai E, Kasper RF. Endometrial thickening (decreased thickness) in response to progesterone exposure leads to optimal pregnancy outcomes with thawed embryo transfer. Fertil Steril. 2019; 112:3:503-509.e1.  https://doi.org/10.1016/j.fertnstert.2019.05.001
  73. Vitali SG, Rimma G, Carugno G, Ciofalo B, Vilos GA, Cianchi S, Budak MS, Lasmar BP, Raffone A, Kahramanoglu I. Hysteroscopy in the treatment of endometrial hyperplasia and cancer in women of reproductive age: new developments and current perspectives. Transl Cancer Res. 2020;9:12:7767-7777. https://doi.org/10.21037/tcr-20-2092
  74. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. Levonorgestrel-releasing intrauterine system versus oral progestogens for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. 2013;28:11:2966-2971. https://doi.org/10.1093/humrep/det320
  75. Raffone A, Travaglino A, Zullo FM, Gencarelli A, Micheli M, Miranda S, De Franciscis P, Insabato L, Di Spiezio Sardo A, Zullo F, Bifulco G. Predictive accuracy of progesterone receptor B in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD insertion. J Minim Invasive Gynecol. 2021;28:6:1244-1253. https://doi.org/10.1016/j.jmig.2020.10.009
  76. Huang P, Fan S, Yu H, Zhang K, Li H, Wang Y, Xue F. Reprogramming of glucose metabolism and its therapeutic potential in obesity-related endometrial cancer. J Transl Med. 2023;21:94.  https://doi.org/10.1186/s12967-022-03851-4
  77. Pavlov AYu, Dzidzaria AG, Kalinchenko SYu, Murav’eva PV. A modern view on the problem: the impact of obesity as a key component of metabolic syndrome on the development and progression of endometrial cancer. Zlokachestvennye opukholi. 2024; 14:2:75-82. (In Russ.). https://doi.org/10.18027/2224-5057-2024-010
  78. Ten AR, Oboskalova TA, Vorontsova AV. Endometrial reception against the background of hormonal therapy in women of reproductive age who have had abnormal uterine bleeding caused by ovulatory disorders. Ginekologiya. 2022;24:4:283-288. (In Russ.). https://doi.org/10.26442/20795696.2022.4.201746
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.